Stay updated with breaking news from Complete Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First survival data from Phase I Dose Expansion in tough-to-treat... | October 25, 2021
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 24, 2021--
The FDA has assigned a PDUFA target date of March 11, 2022 for the New Drug Application for Adlarity.
/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA)...
/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA)...